Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Gains from Sales and Divestitures (2018 - 2025)

Historic Gains from Sales and Divestitures for Whitehawk Therapeutics (WHWK) over the last 2 years, with Q3 2025 value amounting to $387925.0.

  • Whitehawk Therapeutics' Gains from Sales and Divestitures changed N/A to $387925.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $387925.0, marking a year-over-year change of. This contributed to the annual value of $149243.0 for FY2018, which is N/A changed from last year.
  • Latest data reveals that Whitehawk Therapeutics reported Gains from Sales and Divestitures of $387925.0 as of Q3 2025.
  • In the past 5 years, Whitehawk Therapeutics' Gains from Sales and Divestitures registered a high of $387925.0 during Q2 2025, and its lowest value of $387925.0 during Q2 2025.